BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
46.015 EUR
-0.37 (-0.79%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 52 industry peers in the Pharmaceuticals industry. BRM has an average financial health and profitability rating. BRM may be a bit undervalued, certainly considering the very reasonable score on growth BRM also has an excellent dividend rating. With these ratings, BRM could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
In the past year BRM had a positive cash flow from operations.
In multiple years BRM reported negative net income over the last 5 years.
Each year in the past 5 years BRM had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of 6.23%, BRM perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
BRM has a better Return On Equity (32.55%) than 83.33% of its industry peers.
BRM's Return On Invested Capital of 16.42% is fine compared to the rest of the industry. BRM outperforms 79.63% of its industry peers.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 13.72%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM's Profit Margin of 12.57% is in line compared to the rest of the industry. BRM outperforms 51.85% of its industry peers.
BRM has a better Operating Margin (33.51%) than 85.19% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
BRM has a Gross Margin of 73.15%. This is in the better half of the industry: BRM outperforms 61.11% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
BRM has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
Compared to 1 year ago, BRM has a worse debt to assets ratio.
2.2 Solvency
BRM has an Altman-Z score of 2.23. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM's Altman-Z score of 2.23 is in line compared to the rest of the industry. BRM outperforms 42.59% of its industry peers.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.20, BRM is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.41, BRM is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
ROIC/WACC1.94
WACC8.45%
2.3 Liquidity
A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
BRM has a worse Current ratio (1.27) than 64.81% of its industry peers.
BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a Quick ratio of 1.17. This is in the better half of the industry: BRM outperforms 68.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 460.68%, which is quite impressive.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 1.26%.
Measured over the past years, BRM shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
The Earnings Per Share is expected to grow by 35.26% on average over the next years. This is a very strong growth
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.97% yearly.
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.26%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-4.97%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.26, which indicates a very decent valuation of BRM.
Compared to the rest of the industry, the Price/Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 90.74% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.92, BRM is valued rather cheaply.
BRM is valuated reasonably with a Price/Forward Earnings ratio of 8.95.
88.89% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.95 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 90.74% of the companies are valued more expensively.
BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.22 | ||
| EV/EBITDA | 6.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y130.59%
EPS Next 3Y73.3%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 39.80%, which is a nice return.
Compared to an average industry Dividend Yield of 2.20, BRM pays a better dividend. On top of this BRM pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.8% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
FRA:BRM (12/23/2025, 7:00:00 PM)
46.015
-0.37 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap93.68B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target47.16 (2.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.8% |
Yearly Dividend2.05
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)2.69%
PT rev (3m)6.1%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)5.91%
EPS NY rev (1m)1.03%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)1.97%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.95 | ||
| P/S | 2.3 | ||
| P/FCF | 7.22 | ||
| P/OCF | 6.64 | ||
| P/B | 5.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.75 |
EPS(TTM)5.57
EY12.1%
EPS(NY)5.14
Fwd EY11.18%
FCF(TTM)6.38
FCFY13.86%
OCF(TTM)6.93
OCFY15.05%
SpS20.02
BVpS7.73
TBVpS-9.86
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.23 |
F-Score6
WACC8.45%
ROIC/WACC1.94
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.22%
Revenue Next 2Y-4%
Revenue Next 3Y-3.16%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.97%
EBIT Next 3Y49.92%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 478.44% in the next year.